Company profilePharmaceutical#226 of 1,318 in Pakistan1 DRAP alert

LIBRA PHARMACEUTICALS (PVT) LTD

Pharmaceutical company · 79 brands · 75 molecules

Ranked #165 of 311 companies in Drugs For Peptic Ulcer And Gastro-Oesophageal Reflux Disease (Gord)

79 registered products 32 pharmaceutical brands 75 distinct molecules 1 DRAP alert

Company overview

registered products

pharmaceutical brands

distinct molecules

therapeutic classes

DRAP alerts

LIBRA PHARMACEUTICALS (PVT) LTD is a pharmaceutical manufacturer registered with the Drug Regulatory Authority of Pakistan, holding 79 product registrations across 75 distinct molecules. Its portfolio is concentrated in Drugs For Peptic Ulcer And Gastro-Oesophageal Reflux Disease (Gord) and Quinolone Antibacterials. DRAP has issued 1 alert involving its products.

Compiled from the DRAP registry, DRAP approved prices and DRAP alerts, with observed retail from DVAGO and Servaid. Data as of 2026-07-30.

Products by LIBRA

2 products matched in our catalogue — each with its observed price and DRAP approved ceiling.

Antacid 1

Minicol30mlRs 152

Other Beta-Lactam, Cephalosporins & Penems 1

Zatax Plusceiling Rs 237.51

Price ceiling age

DRAP sets a maximum price per registration and revises it only on application. In a market with high inflation, an old ceiling erodes margin in real terms.

ceilings with an approval date

not revised in 2+ years

2026

oldest approval year

20261

Top molecules by brand count

Paracetamol6 brands

Cephradine3 brands

Sulphamethoxazole3 brands

Trimethoprim3 brands

Metronidazole3 brands

Ribavirin2 brands

Omeprazole2 brands

Folic Acid2 brands

Iron Hydroxide Poly Maltose Complex2 brands

Levofloxacin2 brands

Therapeutic classes

Price band (DRAP official ceilings)

Registered products priced by source

DRAP-official5 products · Rs 106.95 – Rs 916.1

DVAGO1 products · Rs 152 – Rs 152

Median across source: Rs 221.48

Regulatory record

1 alert in the DRAP feed we track.

99. Recall Alert (Class-II)- Drug Products Declared Substandard.

2025-10-22

Competitive set

Companies whose registered portfolio overlaps most with this one.

Wilshire Laboratories (Private) Limited32 shared molecules

ZAFA PHARMACEUTICAL LABORATORIES (PVT) LTD.29 shared molecules

GLOBAL BRANDS DISTRIBUTORS29 shared molecules

EFROZE CHEMICAL INDUSTRIES (PVT) LTD.29 shared molecules

Albro Pharmaceuticals28 shared molecules

FYNK PHARMACEUTICALS28 shared molecules

SHROOQ PHARMACEUTICALS27 shared molecules

MEDICRAFT PHARMACEUTICALS (PVT) LTD.26 shared molecules

JAWA PHARMACEUTICALS(PVT) LTD.26 shared molecules

VALOR PHARMACEUTICALS25 shared molecules

Portfolio whitespace

Molecules the closest competitors have registered and this company has not — the starting point for a launch shortlist.

Wilshire Laboratories (Private) Limited holds 131 molecules not in this portfolio

ZAFA PHARMACEUTICAL LABORATORIES (PVT) LTD. holds 156 molecules not in this portfolio

GLOBAL BRANDS DISTRIBUTORS holds 5 molecules not in this portfolio

Get the full profile for LIBRA

This page is a summary. The full company brief adds every registration with its approved ceiling and approval date, per-molecule competitive position, price positioning against the category, and a launch shortlist built from the whitespace above.

Request this brief See what’s included